Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
Authors
Keywords
Trabectedin, Recurrent ovarian cancer, Pooled analysis
Journal
MEDICAL ONCOLOGY
Volume 30, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-02-09
DOI
10.1007/s12032-012-0435-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months.
- (2017) J. del Campo et al. JOURNAL OF CLINICAL ONCOLOGY
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
- (2012) Axel Le Cesne et al. INVESTIGATIONAL NEW DRUGS
- Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
- (2011) R. Wendel Naumann et al. DRUGS
- 8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials
- (2011) N. Colombo et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
- (2010) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
- (2010) Luis Paz-Ares et al. INVESTIGATIONAL NEW DRUGS
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
- (2009) J. M. Del Campo et al. ANNALS OF ONCOLOGY
- Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
- (2009) Philipp Harter et al. Expert Review of Anticancer Therapy
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of homologous recombination in trabectedin-induced DNA damage
- (2008) M. Tavecchio et al. EUROPEAN JOURNAL OF CANCER
- Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers
- (2008) Robert Morris et al. GYNECOLOGIC ONCOLOGY
- Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
- (2008) Yoh Watanabe et al. International Journal of Clinical Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started